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Carcinoma adenoides cysticum
Carcinoma adenoides cysticum is also referred to as
carcinoma basocellulare cysticum, epithelioma mucipa-
rum, basalioma, adenocarcinoma cylindromatosum or
adenomyoepithelioma [1]. According to the WHO
classification the proper name, which directly refers to
the malignant character of this tumour, is carcinoma
adenoides cysticum. This particular tumour develops in
the salivary glands, both large and small. Its most common
site is the mucosa of the oral cavity, the palate and the
paranasal sinuses. It can also be found in the parotid
gland, the submaxillary gland and the additional salivary
glands of the palate. The larynx is a more rare localisation
[1]. It may also appear within the bronchi [2]. The breast
is an extremely rare localisation, although it has been
reported in literature [3].
Carcinoma adenoides cysticum develops slowly,
sometimes over a few decades. It causes late distant
metastases. Metastasising along blood vessels, it reaches
the lungs, the brain, the bones and the liver. Metastases to
local lymph nodes are less frequent. Postoperative
recurrences are common, usually during the first three
years after surgery. The tumour tends to infiltrate para-
neural spaces, therefore it may often cause nerve paralysis
and neuralgia. Multifocal lesions have been reported [4].
On microscopic examination the tumour is well
delimitated, however, in about half of the cases, it
infiltrates local tissues. On histopathological examination,
it possesses a glandular component, which consists of the
proliferating glandulae and the instertitium, with an
abundance of basal membranes. The interstitium may
form a variety of glandulae-derived tubular, trabecular,
compact or cribriform structures (which imitate cribriform
cancer). PAS staining confirms the presence of basal
membranes in the interstitium, and especially within its
cribriform structures.
Because carcinoma adenoides cysticum produces
the carcinoembryonic antigen (CEA), this particular
marker may be used to monitor disease progression.
Prognosis is poor. Approximately 30% of patients
die during the first 5 years. Adjuvant therapy is considered
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a necessity, and despite the relative low radiosensitivity
high dose irradiation is advised (65-82 Gy) [1].
We have diagnosed carcinoma adenoides cysticum in
a 60-year old female patient. She was referred due to
a tumour in the left breast. She had been observing the
tumour for 8 years, and she claimed it had grown and
become painful over the last 18 months. Mammography
and fine needle biopsy were performed. PCI provided
the diagnosis of cancer cells. The encapsulated tumour
was excised whole, within healthy tissue margins and on
histopathological examination, was found to be, to our
disbelief, fibroadenoma mammae – epithelioplasia florida.
The patient remained under very strict follow-up obser-
vation. After 10 months, on examination, we found
a small tumour – 10 mm in diameter – in the medial end
of the postoperative scar. The patient underwent wide
excision of the tumour. On microscopic examination, it
was found to contain three separate tumours, 10 mm,
6 mm and 2 mm in diameter, containing glandular cells
forming cribiform structures. Parts of the lesion had
intraductal characteristics, with central necrosis. Atypia of
a low grade was also found. The final diagnosis was
carcinoma adenoides cysticum et carcinoma ductale in
situ cum invasione focali. We re-examined the specimen
obtained during the first excision and found a focus of
this rare malignancy along the excision margin. In view of
these findings, we performed radical mastectomy modo
Patey. No malignant tissue was found either within the
breast or in the 17 excised axillary lymph nodes. During
immunohistochemical investigation we found poor
positive results for estrogen receptors (+), and positive
results for progestogen receptors (+), protein p53 (+), c-
erb-2 (+) and cathepsin D (+). After surgery we started
tamoxifen therapy. The patient is now under follow-up
and has remained recurrence-free for 22 months after
mastectomy.
Lymphoma malignum
Lymphatic system malignacies seldom appear as primary
tumours of the breast. It is estimated that Non-Hodgkin
Lymphomas account for some 0.1% of all breast
malignancies [5]. On the other hand, only 1% of lympho-
mas are diagnosed as primary breast lesions – as such
a diagnosis can only be pronounced if there are no other
malignancies in any other localisation except for unilateral
axillary lymph nodes. B-cell lymphomas appear to be the
most common – accounting for some 80% of cases. Due
to the extreme rarity of these tumours, the patient groups
reported in literature never contain more than 20 subjects.
Usually one encounters centroblastic lymphomas (diffuse
large B-cell lymphoma, DLCL). Ribrag et al. report
a series of 16 patients treated for DLCL primarily loca-
lised in the breast [6]. Other lymphomas initially diag-
nosed as primary breast tumours include MALT (low-
grade mucosa-associated lymphoid tissue), diffuse large B
cell lymphoma, follicular lymphoma, Burkitt's lymphoma
and MCL (mantle cell lymphoma). The histopathological
picture of the most common of these – the DLCL – is
dominated by a homegenous population of atypical
lymphoid cells (characterised, on immunohistochemical
examination, by a positive reaction for the lymphoid
cell antigen LCA and a negative reaction for cyto-
keratins). These cells infiltrate the interstitium and, rarely,
the lobular and ductal component (imitating carcinoma
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Figure 2. Diffuse large B cell lymphoma H&E staining; enlarged 400X
Figure 1. Carcinoma adenoides cysticum Hematoxylin & Eosin 
(H & E) staining; enlarged 400X
Figure 3. Diffuse large B cell lymphoma, positive reaction to CD20
(immunohistochemical analysis); enlarged 400X
in situ). In this population the majority of cells are
lymphocytes B, characterised by a positive reaction for
the presence of the CD20 receptor. One may also find
a small number of lymphocytes T, characterised by
a weak positive reaction for the presence of the CD3
receptor.
The lesions may be found both in uni- and bilaterally
[7]. The disease is found almost exclusively in women,
although literature presents one case report of a 69-year
old man with gynecomastia and primary lymphoma of
the breast [8]. The authors suggest that the lesion may
have been related to the increased estrogen level in the
male patient. There also exists a report of a 33-year old
female patient diagnosed for bilateral rapid breast
enlargement [9]. Over a period of 6 weeks, both her
breasts increased three-fold. Fine needle biopsy, followed
by surgical biopsy, allowed to establish the diagnosis of
lymphoblastic lymphoma. In the course of further
investigations, including bone marrow examination, the
patient was found to have acute lymphoblastic leukaemia.
In this case, the breasts were the primary sites of the
disease. The breast is also a very rare site for secondary
localisation of lymphoma. Boullanger et al. [10] report
a case of a 71-year old woman diagnosed for fatigue and
neck and axillary lymphadenopathy. In the course of
diagnosis, lesions were also found within the breasts and
the eyelids. Mantle cell lymphoma (MCL) was diagnosed
and the rare localisations of the disease were pronounced
as proof of particular aggressiveness of the disease.
On palpation, one usually finds a sole, movable
tumour. However, the lesions may be wider, without
evident discernible margins. Diagnosis may be set after
histopathological examination, biochemical analyses
(immunoglobulins), bone marrow biopsy, spinal puncture
and imaging techniques.
The treatment of lymphomas of the breast has not
been systematised, due to the few cases observed.
However, over the last few years one may observe
a tendency to move from surgical treatment combined
with adjuvant radiotherapy to chemotherapy combined
with loco-regional irradiation. Ribrag et al. [6] have
presented a paper, in which the majority of patients were
treated according to the CHOP protocol, or similar, i.e.
regimes containing cyclophosphamide, hydroxyrubicine,
vincristine, prednisone and, additionally – VM26 and
bleomycine. The patients had received 3 to 10 courses
(6 on average). In 16 out of 20 patients, complete
remission was achieved, in two – partial remission. Six
patients from this group are dead – four died in the
course of progression to the central nervous system. Some
15% of patients underwent recurrence in the contralateral
breast. Other common recurrence sites were the bones,
the maxillary sinus and the retroperitoneal lymphatic
nodes. Mean follow-up was 54 months (10-144 months).
Overall survival was 67%, while disease-free survival
was 50%.
At the Chair and Clinic of Oncology in Poznaƒ we
diagnosed primary lymphoma of the breast in a 52-year
old woman who had undergone thymoidectomy for
myasthenia gravis 25 years before. She was in very good
condition and had not been receiving any medication.
She sought surgical consultation because of a 3x4 cm
lump in the right breast. We performed a biopsy of the
lesion. The diagnosis was “cellulae atypicae”. The tumour
was excised with wide surgical margins and was, on
examination, found to consist of diffuse large B cell
lymphoma. In all additional investigations, including bone
marrow biopsy, no other sites of disease were found. The
patient received six courses of CHOP over the next 16
weeks. Treatment tolerance was very good. Then, over
the next 8 weeks the patient underwent photon irradiation
(6MeV) – 40 Gy/T to the right breast, 40 Gy/max to both
the cervical lymph nodes and the supraclavicular lymph
nodes and 8.2 Gy/T to the right axillary nodes. Tolerance
of radiation treatment was also very good. During follow-
up examination no recurrence was found either within
the right breast nor in other sites.
Adenomyoepithelioma malignum
Adenomyoepithelioma malignum is a malignant tumour
containing the epithelium and the myoepithelium.
Myoepithelial cells are found between the epithelial cells
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Figure 4. Diffuse large B cell lymphoma, weak positive reaction to
CD3 (immunihistochemical analysis); enlarged 400X
Figure 5. Adenomyoepithelioma malignum H&E staining; enlarged 400X
and the basal membrane. The tumour itself may occur
within the ducts or lobuli of the breast, in the sudori-
parous glands and, especially, in the salivary glands. It
consists of elongated, flat cells, usually discerned using
immunohistochemical methods for the presence of
myosin, cytokeratin, S-100 protein and and kalponin.
Disorders of myoepithelial cell differentiation are being
widely investigated, as they are responsible for the
development of a number of malignancies – adenoid
cystic carcinoma, adenomyoepithelioma (AME), low-
grade adenosquamous carcinoma, poorly differentiated
myoepithelial-rich carcinoma and pure malignant myoe-
pithelioma. The former of these are characterised by slow
growth and seldom metastasise. Pure malignant
myoepithelioma metastasises early, while its charac-
teristics render it similar to sarcomatoid carcinoma [11].
Adenomyoepithelioma may be found in salivary
glands, and, rarely – in the skin and the breasts. The
malignancy is most common in women above 50 years of
age. There exists a report of its occurrence in a 47-year
old man [12]. Its characteristic feature is its mixed texture
– there are case reports of AME co-existent with
sarcomatoid carcinoma and low-grade adenosquamous
carcinoma [13], as well as osteosarcoma and ductal
carcinoma [14]. The least common form (only 12 cases
reported to date) is pure malignant myoepithelioma, i.e.
a tumour consisting only of malignantly differentiated
myoepithelial cells [11].
On palpation, AME is usually found to be
a relatively hard, well-delimited tumour, brownish-white
on cross-section and often containing foci of necrosis.
It seldom exceeds 20-35 mm in diameter, although
some lesions have been found to reach as many as 86 mm
[15-16].
During histopathological examination, one finds
proliferation of glandular elements and of myoepithelial
cells. Glandular elements appear as round, oval or
cylindrical; glandular cells present a positive reaction for
cytokeratins (e.g. the CAN 5.2 type antibody) in
immunohistochemical staining. The myoepithelial cells
appear as fusiform or polyglonal, with hyperchromatic,
atypical nuclei. They infiltrate and overgrow into the
interstitium and around the glandular elements. They
present a positive reaction for smooth muscle actin and
a negative reaction for cytokeratin (e.g. the CAN 5,2 type
antibody) in immunohistochemical staining. Atypical
mitosis may be observed.
Because of so few recognised cases (approx. 55 [17])
there exists no standard treatment. Van Hoeven et al.
have presented an extended case report of 13 patients,
who had undergone mastectomy, and 19 patients treated
with tumour excision. After 12 to 124 months of follow-up
20% of the patients after tumour excision were found to
have local recurrence. Despite this, the authors maintain
that only tumours over 30 mm in diameter ought to be
treated aggressively, than only with local resection [15].
Takashi et al. [18] report the case of a 60-year old woman
who underwent mastectomy for a tumour infiltrating the
skin with uninvolved axillary nodes. Despite radical
treatment, the patient presented with metastases to the
bones, the lungs and the mediastinum. The authors stress
that AME has a tendency to metastasise along blood
vessels, yet up to date there exists no report concerning
metastases from tumours initially less than 20 mm in
diameter [19].
At present the collected data shows, that AME is
a tumour of low malignancy [11]. Local recurrence is
relatively common after lumpectomy, but has only been
observed once after mastectomy. Metastases are rare,
and much more common if the tumour consists of a few
different co-malignancies. In such cases the most common
site of metastases are the lungs.
At the Chair and Clinic of Oncology of the Poznaƒ
University of Medical Sciences we have diagnosed on
case of adenomyoepithelioma malignum in a 63-year old
woman. The patient sought consultation as she had found
a lump in the right breast during self-control. On
palpation, we found a solid, movable tumour 20x30 mm
located between the external quadrants. In mammo-
graphy, the lesion was described as an irregular con-
densation with processes, and in ultrosonography – as
a hypoechogenic lesion 18x13x12 mm in size. Both the
clinical and the radiological picture suggested the
diagnosis of non-metastatic cancer. In order to confirm
this diagnosis we performed small-needle biopsy, which
confirmed the diagnosis of a malignancy. Radical
mastectomy modo Patey was performed. On histo-
pathological examination, the tumour was found to be
20x15 mm in diameter, and appeared as a double-phase
papilloma containing adenosis sclerosans. The internal
part of the lesion contained foci of necrosis. The
interstitium was focally infiltrated by poli-mitotic
mesothelial cells, which suggested that the tumour arose
from malignant differentiation of the myoepithelial parts
of the lesion. Carcinoma ductale in situ was also found
within the lesion, at one point infiltrating the interstitium.
Other histopathological features found within the lesion
included: mastopathia fibrosa et cystica, microcal-
cificationes, fibroadenoma hyalinisans. In the course of
surgery 20 axillary nodes were removed which, on
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Figure 6. Adenomyoepithelioma malignum, positive reaction of
myoepithelial cells to SMA (immunohistochemical analysis); enlarged
400X
histopathological analysis, were found to contain
lymphonodulitis reactiva. In the course of immuno-
histochemical analysis the following markers were found
– CAM 5,2, cytokeratin CK-7, cytokeratin CK-20,
actinomyosin ACT, protein S100. In the course of follow-
up, over a period of 25 months, the patient is free of
recurrence.
Hyperplasia stromalis pseudoangiomatosa
Hyperplasia stromalis pseudoangiomatosa (PASH) often
accompanies benign or malignant lesions within the
breast. It is usually a chance finding in the course of
microscopic examination. In very rare cases, it may form
a palpable lesion. The largest group of patients with
PASH, consisting of 40 women, has been reported by
Powell et al. [20]. The palpable lesions are initially
recognised as fibroadenomas. Material obtained from
small needle biopsy does not allow to discern the cha-
racteristics of PASH which allow to differentiate it from
fibroadenoma or tumour phylloides [21, 22]. On histo-
pathological examination the interstitium significantly
dominates over the lobular and ductal components. It is
necessary to stress that one of the characteristic features
of this malignancy is that the interstitium contains mainly
collagen, in which the vacant places form irregular
patterns adjoining with anastomoses divided by collagen
fibres. In some cases, the free spaces contain erythrocytes.
Myofibroblasts are found on the outskirts of the tumour.
They react positively to cytokeratine and factor VIII on
immunohistochemical examination. The ramified system
of fissures between the fusiform myofibroblasts may cause
the tumour to be erroneously recognised as angio-
sarcoma. Further diagnostic is predominantly immuno-
histochemical. The fusiform cells present a positive
reaction in tests for vimentin (VIM) and for CD34
receptors, and negative reactions with factor VIII. In
a majority of cases, nuclear estrogen receptors cannot be
found [20].  Although this particular hyperplasia usually
occurs in women, yet there have been reports of its
occurrence in men. Damiani and Eusebi [23] describe
two cases of PASH in men with gynecomastia and
concomitant neurofibromatosis.
On palpation, the lesions are well delimitated,
usually a few centimetres in diameter. The largest
reported tumour was 15 cm in diameter [24]. On cross-
section, the tumour is a greyish-white, fibrous and
homogenous.
The aetiology of the disease remains unclear.
Abnormal reactions to endo- and exogenous hormones
suggest a significant influence of hormonal factors on the
development of PASH.
The main treatment method is local excision.
Recurrence is rare – over a follow-up period between 6
months and 11 years (4.5 years on average) we recognised
five local recurrences in a total of 40 patients [20]. Two
patients from this group developed PASH in the contra-
lateral breast. Multifocal lesions are more difficult to
treat and in such cases, simple mastectomy should be
considered.
At the Chair of Oncology of the Poznaƒ University
of Medical Sciences we recognised one case of hyper-
plasia stromalis pseudoangiomatosa in a 19-year old
woman. The patient was referred due to a rapidly growing
mass in the right breast. During the two months after the
initial diagnosis the (tumour) took up some 75% of the
entire volume of the breast. She developed striae on the
skin; the asymmetry of the breasts was considered to be
50%. Ultrasonographically, we found a policyclic,
hypoechogenic tumour with linear liquid-filled spaces.
Cytological analysis was concomitant with benign
fibroadenoma iuvenile giganteum or tumour phyllodes
benignus (lobules of hyperplastic ductal epitelium with
numerous non-atypic myoepithelial cells). We performed
local excision of the tumour. It was well delimitated,
16x12x2.5 cm in size. On cross-section, it was the colour of
flesh, fibrous, with tiny cysts filled with a greenish, viscous
substance. On microscopic examination the picture was
dominated by fibrotically modified breast tissue with its
lobular and ductal structure maintained. We did not
discern any adipose tissue. In order to verify the initial
diagnosis we performed immunohistochemical analysis,
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Figure 7. Hyperplasia stromalis pseudoangiomatosa H&E staining;
enlarged 400X
Figure 8. Hyperplasia stromalis pseudoangiomatosa, positive reaction
to the CD34 marker (immunohistochemical analysis); enlarged 400X
which allowed to discern the following markers: CD34,
VIM, factor VIII, desmin (DES), smooth-mucle actin
(SMA). During the most recent follow-up control, two
months after the surgical procedure, we did not observe
signs of recurrence.
Fibromatosis infiltrativa mammae
The term fibromatosis refers to different forms of
connective tissue proliferation. The histopathological
picture is similar, regardless of the affected organ. The
clinical picture depends upon the anatomical localisation
of the lesion. Fibromatosis may be found in muscles, e.g.
in the sternocleidomastoid muscle (torticollis), the fasciae
e.g. the palmar or plantar fascia (fibromatosis palmaris or
plantaris). Fibromatosis located in the penis is referred to
as Peyronie's disease, and within the ureter as Ormand's
disease. The proliferating and fibrotic connective tissue
causes compression of nerves and blood vessels while the
aggressive growth resembles the growth of a malignancy.
It is often impossible to remove the lesion without any
destruction to the neighbouring structures, while re-
currences are common. There also exist two reports
concerning malignant transformation of fibromatosis into
fibrosarcoma [25].
Fibromatosis of the breast is a rare condition. The
most numerous groups of patients do not exceed 30
women [26, 27]. All the reported cases refer to women.
Pathogenesis remains unknown, however hormonal
(pregnancy) genetic (Gardner's syndrome) or traumatic
factors are often blamed [25]. Lesions have been
described to appear in the direct vicinity a of saline-filled
implant or in the site of fibroadenoma removed one year
earlier. Bilateral tumours have been reported. The largest
tumour was 10 cm in size [27].
On histopathological examination, one finds
policellular interstitium, which dominates over the lobular
and ductal components. It contains myofibroblasts, which
form fasciculi or other forms divided by collagen fibres.
These cells appear in different shapes and sizes, but
seldom are atypic. On immunohistochemical examination,
the reactions to smooth muscle actin and vimentin are
positive, and the reaction to desmin negative.
The recommended treatment is local resection with
a wide healthy tissue margin. Local recurrence is very
common, due to the very long and often indiscernible
outgrowing processes, which infiltrate local tissues.
Wargotz et al. have described a group of 20 patients
treated with local resection of the tumour. Five of them
presented with local recurrence, usually within a couple of
months after surgery. In one case, recurrence was obser-
ved 6 years after surgery. No patient died due to the
disease and in no case did metastases occur [26]. In
another group of patients [27], recurrence was reported in
27% of the cases, usually over an average period of 30
months after surgery. Usually local recurrence was treated
by re-resection with a wide margin, however simple
mastectomies were performed in case of excessive re-
currence or in case of poor anatomical conditions. In
these latter cases reconstruction was suggested approxi-
mately 3 years after surgery, in order to minimalise the
risk of next recurrence [28]. Neither the tumour size, nor
any analysed histological feature did appear to influence
the possibility of recurrence [26].
At the Chair and Clinic of Oncology of the Poznaƒ
University of Medical Sciences we have diagnosed a case
of fibromatosis infiltrativa mammae in a 74-year old
patient. The lesion was found in a mammography scan.
On palpation, we found a lesion 20 mm in diameter,
localised between the two superior quadrants of the right
breast. The patient was referred for surgery with the
initial diagnosis of breast cancer (basing upon clinical
examination and mammography). On excision, we found
a poorly delimited, star-shaped lesion, approx. 1 cm in
diameter. Peripherally, the lesion infiltrated the local
adipose tissues with long ramifications. During
intraoperative histopathological examination, the tumour
was found to contain proliferating, fusiform mesenchymal
cells, while the final histopathological examination
provided diagnosis of fibromatosis infiltriva mammae.
The patient remains under close follow-up scrutiny.
Clinical examination and mammography performed one
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Figure 9. Fibromatosis infiltrativa mammae H&E staining; enlarged
400X
Figure 10. Fibromatosis infiltrativa mammae, positive reaction to
vimentin (immunohistochemical analysis); enlarged 400X
year after the surgical procedure did not reveal any signs
of recurrence.
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